Pakistan Journal of Pharmaceutical Sciences
Cure8 research brief
Why This Matters
This study raises pharmacovigilance signals and mechanistic hypotheses about liraglutide in people with ulcerative colitis — important because GLP-1 drugs are widely used and are being studied for inflammatory effects. However, the work does not prove benefit or harm; it generates questions for further research.
Who Should Pay Attention
Clinicians treating IBD, researchers studying GLP-1 agonists or IBD drug repurposing, and patients with UC who are taking or considering GLP-1 therapies.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This article analyzed spontaneous adverse-event reports in FAERS where liraglutide (a GLP-1 receptor agonist) was listed as the primary suspected drug for patients with ulcerative colitis and combined that signal-detection work with network pharmacology exploring shared molecular targets and pathways.
The FAERS analysis found a mix of common event categories (including gastrointestinal and infection-related reports), some reports coded as “condition aggravated,” and a small number of reports coded as “pre-existing condition improved” that produced an exploratory disproportionality signal.
The authors emphasize these are hypothesis-generating pharmacovigilance observations and do not establish causality, incidence, or efficacy.
The network pharmacology portion identified candidate shared targets and enriched pathways (PI3K/AKT, TNF, JAK/STAT) that the authors suggest could provide biological context for the signals but require confirmation in direct comparative and experimental studies.
If you use GLP-1 drugs or follow research on repurposing them for IBD, this paper flags safety signals and possible mechanistic links worth further study but does not change clinical guidance.
Keep In Mind
This is an abstract-level report combining spontaneous-report (FAERS) disproportionality screening and in silico network pharmacology. FAERS signals can be influenced by reporting bias and cannot establish incidence or causality; the network analyses generate hypotheses that need laboratory and clinical validation.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationPakistan Journal of Pharmaceutical Sciences
PublisherFaculty of Pharmacy and Pharmaceutical Sciences, University of Karachi
AuthorsKeliang Liu
Study typeJournal Article
Indexed viaCrossref
Source typeResearch paper
PublishedOct 10, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Suggestive causal associations between 17 autoimmune diseases and pancreatitis
The study suggests some autoimmune diseases common in IBD patients—ulcerative colitis and primary sclerosing cholangitis—may be genetically linked to higher pancreatitis risk. That could help researchers understand...
Intrinsic capacity, genetic susceptibility and incident inflammatory bowel disease: a prospective cohort study in UK Biobank
The study suggests that a simple, multidomain functional measure (intrinsic capacity) is linked to later IBD risk and that combining it with genetic risk may better identify people at higher risk—especially for Crohn’s...
Real-world patterns of inflammatory bowel disease treatment across adult and pediatric populations: a nationwide cohort study in South Korea
Patients, families, and clinicians may care because the study shows pediatric-onset IBD is more often Crohn's and that children begin advanced therapies earlier than adults. The adult persistence data for vedolizumab and...